Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer

Bibliography

• PARKIN DM, BRAY F, FERLAY J, PISANI P: Estimating the world cancer burden: Globocan 2000. Int. J. Cancer (2001) 94:153-156.
   PubMed Web of Science ®Google Scholar
• PARKIN DM, BRAY FI, DEVESA SS: Cancer burden in the year 2000. The global picture. Eur. J. Cancer (2001) 37(Suppl. 8):S4-S66.
   PubMed Web of Science ®Google Scholar
• SANKARANARAYANAN R, FERLAY J: Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. (2006) 20:207-225.
   PubMed Web of Science ®Google Scholar
• YANG BH, BRAY FI, PARKIN DM, SELLORS JW, ZHANG ZF: Cervical cancer as a priority for prevention in different world regions: an valuation using years of life lost. Int. J. Cancer (2004) 109:418-424.
   PubMed Web of Science ®Google Scholar
• BOSCH FX, DE SANJOSE S: Human papiullomavirus in cervical cancer. Curr. Oncol. Rep. (2002) 4:175-183.
   PubMedGoogle Scholar
• WALBOOMERS JM, JACOBS MV, MANOS MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. (1999) 189:12-19.
   PubMed Web of Science ®Google Scholar
• BOSCH FX, DE SANJOSE S: Chapter 1: Human papillomavirus and cervical cancer burden and assessment of causality. J. Natl. Cancer Inst. Monogr. (2003) 31:3-13.
   PubMedGoogle Scholar
• MUNOZ N, BOSCH FX, DE SANJOSE S et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. (2003) 348:518-527.
   PubMed Web of Science ®Google Scholar
• HO GY, BIERMAN R, BEARDSLEY L et al.: Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. (1998) 338:423-428.
   PubMed Web of Science ®Google Scholar
• RICHARDSON H, KELSALL G, TELLIER P et al.: The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomarkers Prev. (2003) 12:485-490.
   PubMed Web of Science ®Google Scholar
• WOODMAN CB, COLLINS S, WINTER H et al.: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 357:1831-1836.
   PubMed Web of Science ®Google Scholar
• FRANCO EL, DUARTE-FRANCO E, FERENCZY A: Cervical cancer: epidemiology, prevention, and role of human papillomavirus infection. Can. Med. Assoc. J. (2001) 164:1017-1025.
   PubMed Web of Science ®Google Scholar
• BOSCH FX, LORINCZ A, MUNOZ N, MEIJER CJ, SHAH KV: The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. (2002) 55:244-265.
   PubMed Web of Science ®Google Scholar
• REMMINK AJ, WALBOOMERS JM, HELMERHORST TJ et al.: The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer (1995) 61:306-311.
   PubMed Web of Science ®Google Scholar
• FERENCZY A, COUTLEE F, FRANCO E, HANKINS C: Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. Can. Med. Assoc. J. (2003) 169:431-434.
   PubMed Web of Science ®Google Scholar
• SYRJANEN KJ: Natural history of genital human papillomavirus infections. In: Papillomavirus Reviews: Current Research on Papillomaviruses. Lacey C (Ed.), Leeds University Press, Leeds, UK (1996):189-206.
   Google Scholar
• STANLEY MA: Virus-keratinocyte interactions in the infectious cycle. In: Human Papillomaviruses and Cervical Cancer. Stern PL, Stanley MA (Eds.), Oxford University Press, Oxford, UK (1994):116-131.
   Google Scholar
• SEDMAN J, STENLUND A: Co-operative interaction between initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomavirus in vivo and in vitro. EMBO J. (1995) 14:6218-6228.
   PubMed Web of Science ®Google Scholar
• MCDOUGALL JK: HPV immortalisation and transformation. In: Papillomavirus Reviews: Current Research on Papillomaviruses. Lacey C (Ed.), Leeds University Press, Leeds, UK (1996):47-53.
   Google Scholar
• DOORBAR J: Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (2006) 110:525-541.
   PubMed Web of Science ®Google Scholar
• CARTER JJ, KOUTSKY LA, HUGHES JP et al.: Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J. Infect. Dis. (2000) 181:1911-1919.
   PubMed Web of Science ®Google Scholar
• WIKSTROM A, VAN DOORNUM GJ, QUINT WG, SCHILLER JT, DILLNER J: Identification of human papillomavirus seroconversions. J. Gen. Virol. (1995) 76:529-539.
   PubMed Web of Science ®Google Scholar
• WIDEROFF L, SCHIFFMAN MH, NONNENMACHER B et al.: Evaluation of seroreactivity to human papillomavirus Type 16 virus-like particles in an incident case-control study of cervical neoplasia. J. Infect. Dis. (1995) 172:1425-1430.
   PubMed Web of Science ®Google Scholar
• AF GEIJERSSTAM V, KIBUR M, WANG Z et al.: Stability over time of serum antibody levels to human papillomavirus Type 16. J. Infect. Dis. (1998) 177:1710-1714.
   PubMed Web of Science ®Google Scholar
• CARTER JJ, MADELEINE MM, SHERA K et al.: Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. (2001) 61:1934-1940.
   PubMed Web of Science ®Google Scholar
• KIRNBAUER R, BOOY F, CHENG N et al.: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA (1992) 89:12180-84.
   PubMed Web of Science ®Google Scholar
• CAMPO MS: Animal models of papillomavirus pathogenesis. Virus Res. (2002) 89:249-261.
   PubMed Web of Science ®Google Scholar
• HARRO CD, PANG YY, RODEN RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. (2001) 93:284-292.
   PubMed Web of Science ®Google Scholar
• KOUTSKY LA, AULT KA, WHEELER CM et al.: A controlled trial of a human papillomavirus Type 16 vaccine. N. Engl. J. Med. (2002) 347:1645-1651.
   PubMed Web of Science ®Google Scholar
• VILLA LL, COSTA RL, PETTA CA et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. (2005) 6:271-278.
   PubMed Web of Science ®Google Scholar
• VILLA LL, COSTA RL, PETTA CA et al.: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer (2006) 95:1459-1466.
   PubMed Web of Science ®Google Scholar
• SIDDIQUI MA, PERRY CM: Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs (2006) 66:1263-1271.
   PubMed Web of Science ®Google Scholar
• SMITH JF, BROWNLOW MK, BROWN MJ, ESSER MT, RUIZ W, BROWN DR: Gardasil™ antibodies cross-neutralize pseudovirion infection of vaccine-related HPV types. Proceedings of the 23rd International Papillomavirus Conference. Prague, Czech Republic (2006):PL1-PL6.
   Google Scholar
• PAAVONEN J: Efficacy of a quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine against vaginal and vulvar pre-cancerous lesions: a combined analysis. Proceedings of the 23rd International Papillomavirus Conference. Prague, Czech Republic (2006):PL1-PL2.
   Google Scholar
• HARPER DM, FRANCO EL, WHEELER C et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 364:1757-1765.
   PubMed Web of Science ®Google Scholar
• HARPER DM, FRANCO EL, WHEELER C et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet (2006) 367:1247-1255.
   PubMed Web of Science ®Google Scholar
• BRABIN L, ROBERTS SA, FARZANEH F, KITCHENER HC: Future acceptance of adolescent human papillomavirus vaccination. A survey of parental attitudes. Vaccine (2006) 24:3087-3094.
   PubMed Web of Science ®Google Scholar
• GOLDIE SJ, KOHLI M, GRIMA D et al.: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. (2004) 96:604-615.
   PubMed Web of Science ®Google Scholar